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Available online 12 April 2017Introduction: Although the prevalence of chronic obstructive pulmonary disease (COPD) is similar between men
and women, current evidence used to support bronchodilator therapy has been generated in therapeutic trials
that have predominately enrolledmale patients. Here, we determinedwhether there is any signiﬁcant sex-relat-
ed differences in FEV1 responses to ipratropium bromide.
Methods: Data from the Lung Health Study (n = 5887; 37% females) were used to determine changes in FEV1
with ipratropium or placebo inmale and female subjectswithmild tomoderate COPD over 5 years. Lung Expres-
sion Quantitative Trait Loci (eQTL) dataset was used to determine whether there were any sex-related differ-
ences in gene expression for muscarinic (M2 and M3) receptors in lungs of male and female patients.
Results: After 4 months, ipratropium therapy increased FEV1 by 6.0% in female and 2.9% in male subjects from
baseline values (p= 2.42 × 10−16). This effect wasmodiﬁed by bodymass index (BMI) such that the biggest im-
provements in FEV1 with ipratropium were observed in thin female subjects (p for BMI ∗ sex interaction =
0.044). The sex-related changes in FEV1 related to ipratropium persisted for 2 years (p = 0.0134). Female com-
pared with male lungs had greater gene expression for M3 relative to M2 receptors (p = 6.86 × 10−8).
Conclusion: Ipratropium induces a larger bronchodilator response in female than in male patients and the bene-
ﬁts are particularly notable in non-obese females. Female lungs have greater gene expression for theM3musca-
rinic receptor relative to M2 receptors than male lungs. Female patients are thus more likely to beneﬁt from
ipratropium than male COPD patients.








Traditionally, owing to greater cigarette smoking inmen, chronic ob-
structive pulmonary disease (COPD) has been considered a “male dis-
ease”. However, with the marked rise in the smoking rates in women
since the 1960′s, there has been a sharp increase in the burden ofInnovation, St Paul's Hospital,
. This is an open access article underCOPD among women throughout much of the Western world. Today,
in the United States (US), there are 7 million more women than men
with COPD and 10,000 more women than men die from COPD each
year. Currently, the mortality rate is nearly 10 fold higher in women
than in men (3.7%/year in females and 0.4%/year in males) (Ma et al.,
2015). Despite this, ironically, the current management strategies for
COPD (in both men and women) are largely based on therapeutic clin-
ical trials that have recruited mostly male patients. In most therapeutic
trials (even contemporary ones), female patients make up only 20%–
25% of the total cohort (Calverley et al., 2007; Magnussen et al., 2014).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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niﬁcant sex-related differences in the therapeutic responsiveness of in-
haled drugs in COPD. Firstly, there are emerging data that indicate for
the same severity of COPD, as measured by lung function, female pa-
tients have less emphysema and more small airways disease
(Dransﬁeld et al., 2007; Cazzola et al., 2011). Secondly, female patients
with COPD demonstrate greater levels of bronchial reactivity to non-
speciﬁc stimuli such as methacholine compared with male patients for
the same degree of airﬂow limitation (Tashkin et al., 1992). Thirdly,
women may have heightened xenobiotic metabolism of chemicals in-
cluding those related to cigarette smoke andmedications, aswell differ-
ent gene or protein expression (compared to men) of known drug
targets and transporters which may modify the effectiveness of thera-
peutic drugs (Benowitz et al., 2006). Despite these considerations, it is
not known whether there is any signiﬁcant sexual dimorphism in the
way in which men and women respond to commonly inhaled drugs in
COPD (Statista, n.d.; FirstWord Pharma, 2013). The principal aim of
the present study was to determine whether there are any sex-related
differences in bronchodilation related to the use of inhaled ipratropium,
one of themost commonly prescribedmuscarinic receptor antagonist in




To address the primary aim of the current study, we used data from
the LungHealth Study (LHS). The details of LHS have been reported pre-
viously (Anthonisen et al., 1994). Brieﬂy, LHSwas originally designed to
determine the effects of ipratropium and smoking cessation programs
on the rate of decline in lung function over 5 years. At the time of re-
cruitment all subjects were active smokers between the ages of 35
and 60 years (with a mean age of 48 years) who had smoked at least
10 cigarettes a day within the 30 days prior to initial screening and
who demonstrated mild to moderate COPD on spirometry deﬁned by
forced expiratory volume in 1 s (FEV1) of 55% to 90% of predicted, in
the presence of FEV1/forced vital capacity (FVC) ratio of b0.70 after
bronchodilation (mean FEV1 of the cohort was 75% predicted and the
mean FEV1/FVC was 63% post-bronchodilator).
After enrollment, these patients were randomly assigned to one of 3
groups: 1) usual care (UC), who received no intervention, n= 1964; 2)
an intense anti-smoking (special) intervention and ipratropium bro-
mide (Atrovent®, Boehringer Ingelheim Pharmaceuticals) n = 1961
(SIA); or 3) an intense anti-smoking (special) intervention and an in-
haled placebo, n = 1962 (SIP). Subjects were excluded if they had seri-
ous co-morbidities that could have interfered with follow-up or
impacted lung function (e.g. overt heart failure, ischemic heart disease,
or malignancy other than skin cancer). Ten centres participated in the
original study and together they recruited 5887 patients (of whom
37% were females). Those who were in the SIP or SIA groups received
a program that consisted of: 1) a strong recommendation by attending
physician for smoking cessation in an one-to-one encounter; 2) a
group program led by a health educator that met 12 times over
10 weeks, which taught behaviour modiﬁcation techniques; and 3) a
nicotine replacement therapy with nicotine gum (Nicorette Gum, Mar-
ion Merrell Dow Inc), which was provided at no cost to patients. Those
who successfully quit smokingwere enrolled in amaintenance program
to prevent relapses.
2.2. Spirometry and Follow-up
At the baseline visit, a detailed history of respiratory symptoms and
smoking status was obtained. These included years of smoking, number
of pack-years of smoking, current number of cigarettes smoked per day
and the age of initiation. Additionally, all subjects underwentspirometry, which was performed according to the standards of the
American Thoracic Society. Bronchodilator response was measured
after 2 inhalations of isoproterenol (200 μg total dose).
2.3. Interventions
Patients whowere assigned to ipratropium or inhaled placebo were
instructed on the use of metered dose inhalers by a physician and were
asked to use 2 puffs (36 μg) of the inhaler 3 times a day. All subjects
were brought back 4 months following randomization to encourage in-
haler compliance and to determine smoking status. Smoking status was
ascertained by detailed self-report that included the number of ciga-
rettes smoked per day and exposure to any other forms of nicotine
and objectively validated by measuring exhaled carbon monoxide (at
every visit) and salivary cotinine (at annual visits) using well-validated
immunoassays. The cutoff of exhaled carbonmonoxidewas 10 parts per
million (ppm) to denote active smoking and that for salivary cotinine
was 20 ng/ml. All subjects who exceeded any of these thresholds were
classiﬁed as smokers. These objective measures of smoking status
were blinded to patients. Non-smoking was deﬁned at each annual
visit by abstinence from all smoked tobacco products, validated by sali-
vary cotinine and exhaled carbon monoxide. Sustained quitters were
deﬁned as non-smoking at all annual visits from year 1 through year
5. Continuous smokers were deﬁned as smokers at all annual visits
and intermittent quitters were deﬁned as those who were nonsmokers
in at least one annual follow-up visit (Anthonisen et al., 1994). At annual
visits, in addition to the above, spirometry was performed before and
after 2 puffs of isoproterenol. Compliance with inhalers was assessed
by self-report and by weighing the canister. Follow-up was successful
in 90% of patients over these 5 years.
2.4. Gene expression for M2 andM3Muscarinic Receptor Subtypes in Lungs
One important factor that may determine responsiveness to inhaled
therapeutic drugs is the receptor expression for the ligand in lung tissue.
As the LHS did not obtain lung tissue, we used data from the Lung Ex-
pression Quantitative Trait Loci (eQTL) study (Hao et al., 2012) to deter-
minewhether there was a sex-related difference in the gene expression
forM3 (CHRM3) andM2 (CHRM2)muscarinic receptor in lungs of indi-
viduals, who underwent lung resection surgery. The M3 receptor is the
primary muscarinic receptor subtype that induces bronchial smooth
muscle contraction; whereas presynaptic M2's are autoreceptors that
prevent the release of acetylcholine frompreganglionic and parasympa-
thetic nerve ﬁbres and thus negatively regulate the M3 receptor path-
way (Karakiulakis and Roth, 2012). Post-synaptic M2 receptors, which
are also expressed in airway smoothmuscle cells, attenuate adenylyl cy-
clase activity and thus promote smooth muscle relaxation (Montuschi
and Ciabattoni, 2015). Since ipratropium is a non-selective anti-musca-
rinic agent, we used the ratio of M3/M2 (CHRM3/CHRM2) receptor
gene expression in lungs to estimate the potential responsiveness to
ipratropium. The details of the eQTL study have been previously pub-
lished (Hao et al., 2012). Brieﬂy, gene expression proﬁleswere obtained,
using a custom Affymetrix array, which contained 51,627 non-control
probesets, on 1111 lung tissue samples from individuals, who
underwent lung resection surgery for a variety of different clinical indi-
cations, at 3 centres (Laval University, University of British Columbia
[UBC] and University of Groningen). After quality control, the data
were ﬁltered and normalized. Samples that did not pass quality control
were discarded. The ﬁnal dataset contained 964 samples (n = 441 fe-
males; 46% of cohort). On the Affymetrix array, the CHRM3 and
CHRM2 genes were represented by 100154030_TGI_at and
100310990_TGI_at probesets, respectively. The lung tissue expression
data are available at NCBI Gene Expression Omnibus repository (GEO,
http://www.ncbi.nlm.nih.gov/geo) through accession number
GSE23546.
Table 1







Age (years) 48.55 ± 6.56 48.42 ± 6.98 0.71
Body mass index (kg/m2) 24.19 ± 3.98 26.37 ± 3.66 b0.001
Smoking (pack-years) 36.37 ±
16.63
42.86 ± 20.07 b0.001
Cigarettes per day 28.89 ±
11.79
32.68 ± 13.24 b0.001
Age at smoking initiation (years) 18.13 ± 3.92 17.09 ± 3.78 b0.001
FEV1 (litres)b 2.17 ± 0.36 3.08 ± 0.49 b0.001
Subjects in GOLD 1 grade 986 (45.13%) 1728 (46.68%) 0.26
Subjects in GOLD 2 grade 1198
(54.83%)
1970 (53.21%) 0.24
Bronchodilator response (% of baseline
FEV1)
4.31 ± 5.35 4.27 ± 4.95 0.99
SIA 769 (35.19%) 1192(32.20%) b0.05
SIP 706 (32.31%) 1256(33.93%) 0.21
PC 20 (mg/ml) 6.35 ± 5.44 8.62 ± 6.61 b0.001





Data are presented as mean ± SD for continuous variable and number of subjects (% col-
umn totals).
Abbreviations: FEV1, forced expiratory volume in 1 s; GOLD, Global initiative for chronic
Obstructive Lung Disease; PC, provocation concentration at which there is 20% fall in
FEV1; SIA, special intervention + Atrovent; SIP, special intervention + placebo.
a O'Connor Slope is deﬁned as the percentage of decline of FEV1 from the post-saline
value to the valuemeasured after theﬁnalmethacholine dose administereddivided by the
ﬁnal cumulative methacholine dose administered.
b All values are post-bronchodilator.
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To compare the baseline characteristics between male and female
subjects, we used Wilcoxon rank sum test for continuous variables
and chi-squared test for discrete variables. Because ipratropium induces
acute bronchodilation but does not modify the long-term decline in
FEV1 (Cheyne et al., 2015) to evaluate the possible differential effects
of ipratropium in female versusmale subjects,we restricted our analysis
to subjects in the SIA group of LHS who came back for spirometry at
4month post-randomization.We chose the 4month time point because
compliance with ipratropiumwas greatest at this follow-up (compared
with all the subsequent follow-up) with a rapid decay in compliance by
1 year post-randomization (Cheyne et al., 2015). We compared the
mean changes in post-bronchodilator FEV1 from baseline to 4 months
betweenmen andwomen using a two sample t-test. Amultiple variable
linear model was then used to evaluate the effects of sex on the change
of % predicted FEV1 at 4 months from baseline values in subjects who
were in the SIA group. In this model we adjusted the results for age,
body mass index (BMI), smoking intensity (as deﬁned by exhaled car-
bon monoxide) and pack-years of smoking and also included a sex-
BMI interaction and sex-pack-years interaction terms. To determine
the impact that sex had on FEV1 changes over 5 years, we used linear
models which were adjusted for smoking status at each annual visit.
For the lung eQTL dataset, we compared baseline characteristics be-
tween females andmales usingWilcoxon rank sum tests for continuous
variables and chi-squared tests for discrete variables.
The difference in the ratio of M3/M2 receptor gene expression be-
tween females and males was conducted for each sub-cohort (Laval,
UBC, Groningen) separately, using linear models adjusting for age and
smoking status. The results were then combined using inverse variance
weighted meta-analysis assuming a ﬁxed effect model. All analyses
were conducted using R version 3.2.1.
3. Results
3.1. Baseline Characteristics of LHS
The baseline characteristics of the LHS cohort according to sex are
summarized in Table 1. While there were no sex-related differences in
age or the percent predicted post-bronchodilator FEV1 of the subjects,
female participants had lower BMI's and reduced cigarette smoke expo-
sure, as evidenced by lower pack-years of smoking and older age of
smoking initiation. As reported previously (Kanner et al., 1994), female
subjects had increased airway responsiveness to methacholine.
3.2. Spirometry Values at 4 Months Following Randomization
The subjects in the SIA and SIP groups returned to the clinical centres
at 4 months post-randomization to undergo spirometry. The mean
change in post-bronchodilator FEV1 from baseline was 0.10 L in the
SIA group versus−0.09 L in the SIP group (p = 1.37 × 10−164). When
FEV1 was expressed as a percent predicted value, the mean change
was 3.32% in the SIA group versus−2.33% in the SIP group (p = 3.66
× 10−166).
The change in FEV1 at 4 months from baseline values in female ver-
sus male subjects who were randomized to SIA is shown in Table 2.
Overall, in the SIA group, the female subjects experienced a 4.85% ±
5.66% increase in their predicted FEV1 from baseline; whereas in male
subjects, they experienced a 2.34% ± 5.50% increase in their predicted
FEV1 from baseline (p= 2.61 × 10−19 which compares the female ver-
sus male FEV1 responses to ipratropium). Based on the recommenda-
tions of the ATS/ERS Task Force, we deﬁned a clinically relevant
improvement in FEV1 as a change in FEV1 of 140 ml or greater from
baseline values (Cazzola et al., 2008). Using this threshold, 44.1% of fe-
male subjects versus 37.4% of male subjects experienced a signiﬁcant
improvement in their lung function at 4 months with ipratropium (p=0.0066). In contrast, 15.2% of female and 31.4% ofmale subjects expe-
rienced a reduction in FEV1 with ipratropium. In those in the SIP arm,
there was a slight reduction in FEV1 from baseline (−2.33% ± 5.84%)
withmale subjects experiencing a slightly greater fall in FEV1 compared
with female subjects (male−2.75% ± 5.46% versus female−1.58% ±
6.38%, p = 0.0001) when FEV1 was evaluated as a percent predicted
value.
In the multivariable analysis where we evaluated the differential ef-
fects of ipratropium on % predicted FEV1 at 4 months (Table 3), we
found that there was a signiﬁcant interaction between sex and BMI. In
females, the bronchodilatory effect of ipratropium bromide was in-
versely related to the subject's BMI; whereas in males, BMI had little ef-
fect on ipratropium's bronchodilatory effect (Fig. 1).
3.3. Spirometry Values From Baseline Through Year 5 Following
Randomization
Over 5 years, among individuals in SIA and SIP groups, fewer female
thanmale subjects were able to become sustained quitters (p= 0.010).
However, among continuous smokers, females smoked fewer cigarettes
per day than male smokers (p = 0.00004). Despite these differences,
the average percent predicted FEV1 at year 5 was similar between
males and females (p = 0.42), with a similar rate of % predicted FEV1
change per year over these 5 years (p = 0.06). These data are summa-
rized in Table 4. Although the use of ipratropium did not modify the
rate of decline in % predicted FEV1 over the 5 years, its effect on FEV1
was signiﬁcantly greater in females versus males until year 3 for those
assigned to SIA (Fig. 2).
3.4. Gene Expression for M2 and M3 Receptors in Lung Tissue
Because LHS did not collect lung samples for gene expression stud-
ies, we evaluated gene expression levels for the M2 (encoded by the
CHRM2 gene) andM3 (encoded by the CHRM3 gene)muscarinic recep-
tor in lungs of individuals who underwent lung resection surgery (n =
436 females and n=517males). The baseline characteristics of the lung
Table 2
FEV1 changes from baseline to 4 months visit in male and female subjects in the special intervention + Atrovent (SIA) group.a
Women (n = 683) Men (n = 1061) p-Value
Change in FEV1 (litres) 0.13 ± 0.15 0.08 ± 0.22 b0.001
Change in FEV1 (% change from baseline) 6.00 ± 7.51 2.94 ± 7.53 b0.001
Change in FEV1 (change in % predicted FEV1) 4.85 ± 5.66 2.34 ± 5.50 b0.001
Individuals who experienced a 140 ml or greater increase in baseline FEV1 301 (44.07%) 397 (37.42%) b0.01
a All values are post-bronchodilator.
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slightly younger and had lower BMI, and smaller pack-years of smoking
exposure thanmale subjects. There was increased lung gene expression
of M3 receptor relative to the M2 receptor in female versus male lungs
(meta-analysis p value of 6.86 × 10−8 adjusted for age and smoking;
Fig. 3).WhenM3 receptor expression in lungwas evaluated in isolation,
there was greater M3 receptor expression in female versus male lungs
(meta-analysis p value= 0.0047; Supplementary Fig. 1) though adjust-
ments for age and smoking abolished these differences (p = 0.14).
4. Discussion
Despite the high burden of COPD in women, the current therapeutic
strategies for COPD have been derived from clinical trials that have
largely recruited male subjects (Vogelmeier et al., 2017). Using data
from the LungHealth Study (LHS),whichwasmade up of nearly 40% fe-
male subjects, we found that on average women experienced a larger
bronchodilatory beneﬁt of ipratropium compared with male subjects.
Signiﬁcantly, these effects were modiﬁed by BMI such that females in
the lowest BMI categories experienced the largest beneﬁts. At 4months
of therapy, 44% of the female subjects demonstrated a signiﬁcant im-
provement in FEV1 (deﬁned by an increase of 140 ml or more in their
FEV1 from baseline) from ipratropium; whereas only 37% of the male
patients met this threshold.
Our ﬁndings are consistent with the evolving concept that for the
same cigarette exposure, female COPD patients have a greater burden
of airway disease than male patients and that this risk may bemodiﬁed
by body mass index and presence of comorbidities (Dransﬁeld et al.,
2007; Cazzola et al., 2011; Cazzola et al., 2013). For instance, in patients
undergoing lung volume reduction surgery, female lungs demonstrated
greater wall thickening in small airways (b2 mm in size) than male
COPD lungs (Martinez et al., 2007). These changes appear to occur
early in the disease process, as using optical coherence tomography,
we showed previously that female smokers have thicker airway walls
than male smokers even when their FEV1 was within the normal
range (Tam et al., 2016).These human ﬁndings have been supported
by data in murine models of COPD where exposure to 6 months of cig-
arette smoke resulted in signiﬁcantly greater airway disease in female
compared with male mice (but no signiﬁcant differences in the extent
of emphysema) (Tam et al., 2016). Themechanisms responsible for sex-
ual dimorphism of COPD are largely unknown. In animals, removal of
ovaries in female mice completely abolished the sex-related differences
in the airway disease induced by cigarette smoke, suggesting thatTable 3
Risk factors associatedwith signiﬁcant changes in percent predicted FEV1 from baseline to
4 months in subjects who were assigned to ipratropium bromide.
Risk estimate 95% CI p-Value
Sex (male versus females) −5.50 (−9.31,−1.68) b0.01
Age (per 1 year increase) −0.07 (−0.12,−0.03) b0.01
BMI (per 1 kg/m2 increase) −0.14 (−0.25,−0.03) b0.05
CO (per 1 ppm increase) 0.02 (0.01, 0.04) b0.01
Smoking (per 1 pack-year increase) 0.04 (0.01, 0.07) b0.01
Sex × BMI 0.15 (0.00, 0.30) b0.05
Sex × pack-years −0.02 (−0.05, 0.01) 0.233
Abbreviations: BMI, body mass index; CI, conﬁdence interval; CO, carbon monoxide.female sex hormones may be involved in the process. However, it
should be noted that there are translational limitations to animal stud-
ies in COPD, which have been previously highlighted (Churg et al.,
2011).Thus, these data should be interpreted cautiously. Notwithstand-
ing, in LHS and other studies (Langdeau et al., 2009; Tantisira et al.,
2008), it has been shown that female smokers have increased airway re-
sponsiveness compared with male smokers, which may be related to
their reduced airway geometry or increased small airway inﬂammation
(Cohen et al., 2008; Sheel et al., 2009) and female COPD patients are
more likely to have asthma overlap (Sin et al., 2016), which may in-
crease airway responsiveness to bronchodilators (Montuschi et al.,
2014). Supporting these data, animal experiments have shown that fe-
male mice compared with male mice demonstrate greater levels of
bronchial responsiveness and airﬂow limitation related to viral infec-
tions in the respiratory tract (Larcombe et al., 2011). In female mice,
bronchial reactivity increases with age; whereas in male mice, age
plays no role (McKenzie et al., 2010). Whether these sex-related differ-
ences in airway reactivity explain differential responses to bronchodila-
tors in COPD is not known.
Ipratropiumbromide induces bronchodilation by reducing choliner-
gic tone in the airway smooth muscles by competitively binding to the
muscarinic (M) acetylcholine receptors in the airways (Gross, 1988). Al-
though ipratropium is a non-selective anti-muscarinic agent, its effect in
the lungs is mediated largely through the M3 receptor, which upon ac-
tivation causes smoothmuscle contraction (Montuschi et al., 2013). The
M2 receptor, on the other hand, auto-regulates acetylcholine (ACh) sig-
naling by inhibiting ACh release by preganglionic and parasympathetic
neural tissue (Alagha et al., 2014), though in the post-synaptic neural
tissue, its stimulation may promote airway smooth muscle relaxation
(Montuschi and Ciabattoni, 2015). In lung tissues, we observed a mod-
est upregulation of M3 receptor and most importantly a signiﬁcant in-
crease in M3 gene expression relative to M2 receptor expression in
the lungs of female comparedwith male subjects, raising the possibility
that there may be sexual dimorphism in the expression of these recep-
tors in the airways that may modulate therapeutic responses to
ipratropium. Additional studies will be required to validate these early
observations.
We also observed a signiﬁcant interaction between sex andBMI such
that in females the bronchodilatory effects of ipratropiumwere inverse-
ly associated with BMI; whereas inmales, BMI did not appear to modify
this effect. Although there is a scarcity of studies that have evaluated the
potential modifying effects of BMI on bronchodilatory responses in
COPD, in asthma, obesity has been shown to reduce acute bronchodila-
tor responses to short-acting beta-2 agonists (McGarry et al., 2015). The
molecular basis of these observations remains elusive and further stud-
ies will be required to fully understand the complex relationship be-
tween sex and body mass in COPD.
There were limitations to the study. Firstly, ipratropium is a non-se-
lective anti-muscarinic agent and is a relatively weak bronchodilator.
This, the ﬁndings may not be generalizable to the newer more selective
M3 inhibitors such as tiotropium,which are commonly used in the com-
munity and are generally more efﬁcacious than ipratropium (Cheyne et
al., 2015). Using theUPLIFT (Understanding the Potential Long-term Im-
pact of Tiotropium) data, Tashkin et al. data showed that there were no
signiﬁcant differences in the responses to tiotropium, a more selective
M3 inhibitor, between men and women with respect to FEV1 decline
Fig. 1. The differential impact of body mass index in men and women on the bronchodilatory effects of ipratropium bromide over 4 months. The plot is a set of ﬁtted lines based on a
multivariate regression analysis in which age, sex, BMI, smoking have been adjusted. P for interaction = 0.044.
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sufﬁcient power to adequately address this issue because only 25% of
the cohort were female patients and 40% of patients (andmore females
than males, 45% versus 40%) discontinued the study prematurely. Sec-
ondly, although we observed signiﬁcant sex-related differences in
FEV1 at 4 months and at 1 and 2 years of follow-up, these differences
were largely lost beyond this time point. One likely explanation for
this observation is the reduction in compliance with ipratropium over
the 5 years of follow-up. Whereas the mean use of ipratropium was
4.4 puffs per day at 4 months of follow-up, by year 1, it was 3.67 puffs
per day and by year 5, it was b3 puffs per day (Kanner et al., 1994).
The progressive reduction in compliance to themedication likely atten-
uated the sex-related differences in FEV1 related to ipratropium over
time. Thirdly, while FEV1 is an important endpoint for assessment of
therapeutic efﬁcacy of bronchodilators, there are other patient-centered
outcomes such as exacerbation that are also relevant in their therapeu-
tic assessment. LHS was powered on FEV1 decline and as such robust
data on exacerbations or health status were not available. Furthermore,
LHS did not perform computed tomographic (CT) scanning and as such
the effects of COPD phenotypes (emphysema versus small airways dis-
ease) on therapeutic responsiveness could not be assessed. Fourthly,
LHS recruited individuals with mild to moderate COPD. Thus, the ﬁnd-
ings of this study may not be applicable to patients with severe or
very severe COPD. It should also be noted that LHS was conducted in
the 1990′s when smoking rates were signiﬁcantly higher and COPD
management was signiﬁcantly different than the current standards.Table 4
Smoking behaviour and FEV1 changes over 5 years in men and women.
% predicted FEV1 at year 5a
Change in FEV1 from baseline (% of baseline)
Change in % predicted FEV1 from baseline (% of baseline)
Sustained quitters at year 5
Intermittent quitters at year 5
Continuous smokers at year 5
Mean number of cigarette smoked per day at year 5 (for continuous smokers)
Exhaled CO levels (for continuous smokers; parts per million)
Cotinine levels (for continuous smokers; ng/ml)
a All FEV1 values are post-bronchodilator.We also noted in this study that females on average smoked fewer cig-
arettes than male patients. Since cigarette smoking induces a persistent
inﬂammatory response in the lung that leads to tissue injury and dys-
function, the sex-related differences in therapeutic responses to
ipratropiummay in part be related to differences in smoking behaviour
between men and women (Malerba and Montuschi, 2012). Moreover,
the lung samples were obtained from patients who underwent lung re-
section surgery, which may limit the generalizability of the results. Be-
cause the two studies (LHS and the Lung eQTL studies) were
conducted in different subjects with different clinical characteristics,
their results are not directly comparable.
The burden of COPD is rapidly growing in the female population. The
ﬁndings of the present study indicate that female COPD patientsmay be
more responsive to bronchodilators (in terms of FEV1) and this effect is
modiﬁed by body mass index. In an era of precision medicine, there is
compelling and pressing need for future therapeutic trials to include
sufﬁcient numbers of female patients to ensure generalizability of ﬁnd-
ings to both men and women and to enable sex and gender based as-
sessment of therapeutic responsiveness to novel therapies in COPD.Funding Sources
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